MFN Drug Pricing Targets: Lowering U.S. Drug Costs Through International Alignment

By Rene Pretorius

May 21, 2025

Summary

The U.S. Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) have set Most-Favored-Nation (MFN) drug pricing targets. This policy aims to align U.S. drug prices with those in other economically comparable countries. The goal is to lower U.S. drug prices significantly without compromising innovation.

Key Insights

  • MFN Pricing Model: The MFN policy targets pharmaceuticals without generic or biosimilar competition. It aims to reduce prices by aligning U.S. prices with the lowest among OECD countries with a GDP per capita of at least 60% of the U.S.
  • Impact on Pricing: U.S. drug prices are often three to five times higher than those abroad. The MFN policy aims to reduce these disparities.
  • Expected Outcomes: The Trump administration expects a 30% to 80% reduction in drug prices.

Background Context

The MFN model addresses global disparities in drug pricing. The Trump administration previously proposed an International Pricing Index (IPI) model. It was later rescinded by the Biden administration. The current policy continues efforts to ensure U.S. patients pay comparable prices to those in other developed countries.

Implications

  • Health Economics: The MFN policy could save costs for patients and healthcare systems. However, it may impact pharmaceutical company profits and R&D investment.
  • Innovation and Access: The model aims to preserve innovation. Yet, it remains unclear how pharmaceutical companies will adapt, potentially affecting new treatments.
  • Global Impact: The policy could influence global drug pricing strategies. It may also lead to disputes with pharmaceutical companies and other countries.

For further details, explore the official announcement from HHS.

Reference url

Recent Posts

Navigating Challenges for Small Countries to Access Innovative Medicines

By João L. Carapinha

July 31, 2025

Access to innovative medicines is a pressing issue for patients in smaller European countries. These nations often face significant barriers in obtaining timely and equitable healthcare solutions. The article "Ensuring access to innovative medicines for patients in smaller countries" (linked belo...
Mental Health Policy Integration: A Cross-Sector Imperative for Well-being and Productivity
The purpose of this update is to review a recent Lancet editorial (linked below) on mental health policy integration in public policy frameworks. The article “Mental health in all policies” emphasizes that mental health influences individual well-being, societal cohesion, and economic productivit...
Novartis Gains Approval for Groundbreaking Malaria Treatment for Infants

By Rene Pretorius

July 30, 2025

In this article we review Swissmedic's approval of Novartis' Coartem Baby. It is the first malaria treatment for infants under 4.5 kilograms. This novel formulation addresses a critical gap in antimalarial care. Existing treatments were unsuitable due to dosing and metabolism concerns in young in...